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Women infected by the human immunodeﬁciency virus (HIV)
also have a high prevalence of human papillomavirus (HPV) infec-
tions with the presence of multiple HPV types being typical (Levi
et al., 2004). Furthermore, the incidence of cervical abnormalities is
signiﬁcantly higher than in immunocompetent hosts, with these le-
sions likely to be difﬁcult to eradicate (Ellerbrock et al., 2000). Inva-
sive cervical cancer (ICC) is considered one of the Acquired Immune
Deﬁciency Syndrome (AIDS)-deﬁning conditions (Bower et al.,
2006). However, the true relationship between HIV infection and cer-
vical cancer is controversial. It has been postulated that in the era of
highly active antiretroviral therapy (HAART), longer survival would
allow for the development of ICC, thus an increase in the incidence
of ICC was expected to be observed. After more than 10 years of the
introduction of HAART, this expected increase does not seem to be
taking place (Massad et al., 2009). Persistent infection with one or
more high risk HPV genotypes is a necessary cause for the develop-
ment of ICC, with HPV 16 and 18 responsible for a large proportion
of the cases, although with minor differences among geographical re-
gions. HPV 11 presents a low-risk for cervical cancer, causing benign
hyperproliferative lesions as genital warts and oral papillomatosis.⁎ Corresponding author at: Lab de Virologia, LIM 52, Instituto de Medicina Tropical
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acuminata lesions from HIV immunosupressed and otherwise healthy
patients, always in association to a low-risk HPV type, either HPV 6 or
11 (Brown et al., 1999). Conversely, low-risk HPV DNA types were
found in high-grade lesions, but again in association with high-risk
HPV types (Clifford et al., 2006), making it difﬁcult to attribute causal-
ity to a speciﬁc genotype.
In a retrospective cross-sectional study, which analyzed 10,575
cases of ICC from the ﬁve continents in between 1949 and 2009,
only 16 cases were described to harbor a single infection with a low
risk HPV. Among them, only 2 were HPV-11 positive (De Sanjosé
et al., 2010). A recent study carried out on HIV-infected ICC patients
and HIV negative ICC cases from Kenya, found one case of a HPV-11
positive ICC patient in the context of a multiple infection, and, sur-
prisingly, two cases in the HIV-negative group of ICCs containing
HPV 11 and 40 as single infections (De Vuyst et al., 2008).
In this case report, we describe a case of metastatic ICC harboring
HPV-11 occurring in an HIV-infected patient.
Case report
A 38-year-old HIV-infected female patient presented to the outpa-
tient clinic of Instituto do Câncer do Estado de São Paulo (ICESP), Bra-
zil, complaining of vaginal bleeding. Examination aided by a
speculum revealed an exophytic lesion that was biopsied. The speci-
men was sent for histopathologic examination and for HPV genotyp-
ing (Virology Laboratory of Instituto de Medicina Tropical).
Cervical squamous cell carcinoma was diagnosed. Pelvic magnetic
resonance imaging revealed a large cervical tumoral lesion invading
the right parametrium and the posterior vaginal fornix. The patient
underwent radiotherapy. At two months follow up, the patient com-
plained of enlarged neck lymph nodes that were biopsied and also sent
for histopathologic examination. Both primary and metastatic samples
were diagnosed as squamous cell carcinoma. Palliative chemotherapy
with cisplatin was performed. After four months, the patient developed
acute bowel obstruction due to progression of the disease and died.
Methods
In situ HPV DNA detection was performed with biotinylated
probes Y1411 HPV types 6/11 DNA Probe Mix and Y1443 GenPoint
HPV, biotinylated DNA Probe targeting sequences of “high-risk” HPV
Fig. 1. Alignment of HPV alpha E6 amino acid sequences, including HPV low risk types (HPV-6 and 11), HPV high risk types (HPV-16, 18, 31, 33 and 53) and this isolate. Region
between position 33 and 47 represents a proposed E6-AP binding domain. Arrow points to the amino acid at position 31 which is associated to p53 degradation (ref. Massad
et al., 2009). “.” Indicates identical residues to the HPV-11 E6 sequence (GenBank Entry # FN907963).
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ampliﬁcation was developed with K620 (GenPoint, Dako, Carpinteria,
CA, USA).
DNA was extracted from fresh tumor using QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany) and HPV genotyping was carried out with
the PapilloCheck Kit (Greiner Bio-One, Frickenhausen, Germany).
DNA was extracted from slices of the parafﬁn-embedded lymph
nodes by the Genomic DNA Extraction kit (Real Biotech Inc., Taiwan)
and submitted to HPV genotypingwith the INNO-LiPA HPV Genotyping
v2 (Innogenetics, Gent, Belgium), which employs PCR ampliﬁcation fol-
lowed by hybridization to solid-phase immobilized oligonucleotide
probes. As it has been described that the absence of a basic amino acid
motif at position 31 of the HPVs E6 proteins is strongly correlated to
their p53 degradation activity (Fu et al., 2010) we reasoned whether
this particular oncogenic HPV 11 isolate would bear a non-basic motif
at this key position. An 789 bp E6/E7 amplicon was generated from
fresh cervical tumor DNA by PCR ampliﬁcation with the primers for-
ward 5′ GGAGGGACCGAAAACGGTTCAACCGA 3′ and reverse 5′
TGGTGCGCAGATGGGACACACAA 3′. Puriﬁed PCR product was se-
quenced in an automatedABI PrismABI 3100Genetic Analyser (Applied
Biosystems, California, USA).
Molecular ﬁndings
Fresh tumor DNA submitted to the Papillocheck, which targets the
HPV E1 gene and parafﬁn-embedded metastatic lymph nodes tissue
DNA tested by the Inno-Lipa HPV, targeting the HPV L1 gene, revealed
the single presence of HPV-11. In contrast, “in-situ” hybridization did
not depict any HPV type on the lymph nodes sections. Comparative
analysis of the E6 sequence demonstrated a high similarity to an
HPV-11 reference strain (GenBank Entry# FN907963). In the visual
inspection of the E6/E7 alignment, a positively charged basic residue
(K=lysine) in position 31 of E6 gene was observed (Fig. 1).
Discussion
This case report illustrates an ICC associated to a HPV-11 single in-
fection, what is almost exclusively found in benign lesions. Little is
known about the mechanism of HPV-11 associated carcinogenesis be-
cause of its rare occurrence. In this study, we tried to envisage a poten-
tial biochemicalmechanism responsible for this enhanced transformingactivity by a non-oncogenic type, i.e. E6 point mutation in position 31.
We observed lysine, a positively charged residue, in the position 31 of
E6 sequence, which displays weak p53 degradation activity. Host bio-
logical factors (Nicol et al., 2008) beyond CD4 cell-count, may have
played an important role on this rare neoplasic occurrence.
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